Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study for Transplant Ineligible Patients with Multiple Myeloma

Shots:

  • The P-III TOURMALINE-MM2 study involves assessing of Ninlaro + lenalidomide + dexamethasone vs PBO + lenalidomide + dexamethasone in 705 transplant-ineligible patients with newly diagnosed MM
  • The P-III TOURMALINE-MM2 study results: improvement in PFS (35.3 mos. vs 21.8 mos.); safety profile is consistent with the existing prescribing information
  • Ninlaro is an oral proteasome inhibitor, approved in 60+ countries, including the US, EU & Japan with 10+ regulatory filing currently under review. In 2015, the US FDA has approved the triple regimen to treat patients with MM prior treated with at least one therapy

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Twitter